The Procaine-Base-Infusion: a Review after twenty Years of Use

Ralf Oettmeier, MD[1] and Uwe Reuter, MD[2]

[1]*Paracelsus Clinic Lustmühle, Battenhusstrasse 12, CH-9062 Teufen, Switzerland.*

[2]*Klinik im Leben, Gartenweg 5-6, D-07973 Greiz, Germany.*

*Correspondance:
Ralf Oettmeier, Rietli 736, CH-9056 Gais, Switzerland, E-mail: Ralf.Oettmeier@gmx.de.

Received: 28 September 2017; **Accepted**: 17 October 2017

ABSTRACT

The highly-dosed infusion with Procaine-HCl with sodium-bicarbonate as additive was firstly published twenty years ago. The method advanced to a routine in many centers for pain treatment, rehabilitation and natural medicine. The aim of the procedure is the systemic use of the various pharmacological features of Procaine, especially to inhibit pain and inflammation, for vasodilatation, anti-oxidation and to harmonize the vegetative nervous system. On one hand shall the addition of sodium-bicarbonate balance the common latent pH-decrease in the periphery. On the other hand also the degradation products of Procaine (DAE and PABA) have a systemic effect. For the safety of the patients and to improve the success rate of the method it was shown that the classic Procaine-Base-infusion should be only realized on the base of a prior acid-base-diagnostic.

Keywords

## Procaine - The "Polycrest" of Anesthetics

The local anesthetic Procaine is characterized by a sum of pharmaceutical features. With this in mind Prof. ASLAN, the founder of the eponymous therapy, spoke of it as vitamin-like action beside the anesthetic effects [1]. Further benefits of Procaine are its good tractability and low-grade toxicity due to its short half-life and plasma degradation, the capillary impermeability effect [1], the inhibition of inflammation [2-5], antioxidative and fat-reducing action [6-8]. Contrary to all other anesthetic drugs it causes vasodilatation of vessels and capillaries [9-14]. Therefore, with this therapy it is possible to reach and optimally influence very poorly circulated tissue (especially in case of inflammation and pain). Beside the effect of blocking voltage-dependent sodium channels with the result of a short-term anesthesia [15], additional actions of Procaine on cell membranes and the matrix as well as sympatholytic actions were also discussed [16-21]. KRAUSE has demonstrated that the anti-inflammatory effect of Procaine in rheumatic disease was especially high when combined with an alkali additive [7]. In the field of oncology, the effect of Procaine to reduce side effects from radiotherapy [22,23] or to improve the influence of chemotherapy [24-27] is reported. Furthermore,

a wide epigenetic action of the procaine has been demonstrated. A growth-inhibition after incubation with human cancer cells due to the partial blockade of DNA-methylase in vitro was described in 2003 [28]. A diminishing effect of the proportion of 5-methylcytosine into global genomic DNA and cell proliferation due to procaine was reported in a study of tumour suppressor genes [29]. In the same way, inhibition of DNA methylation in human hepatoma cells was found by TADA et al. [30]. In 2016, SABIT et al., showing that the use of procaine combined with carboplatin was the most effective treatment for diminishing the global level of DNA methylation in colon cancer cells [31]. Well examined is also the central modulation of Procaine acting on the stress axis of limbic system with anti-depressive and psycho-analeptic action [32-36].

The Procaine-Infusion – the logic following of other parenteral applications

Depending from the amount of administered Procaine it is possible to increase the effect to influence pain, inflammation and to reach the other described features of the substance (Figure 1). Since a long time it is prevalent to finish a neural therapy session with an i.m. or i.v. shot of 25 till 50 mg Procaine to reach a systemic action. The pure Procaine infusion was firstly described by SEIFEN et al. [37,38] and was mostly used as a continuous treatment in cases of acute pancreatitis [39-41] and for epidural anesthesia in infants,

children and risk patients, which underlines the low toxicity of the substance [42-49]. O´DONNELL et al. reported about the use of procaine infusion to block the cardiac nerves [50].

Figure 1: Fields of parenteral Procaine applications.

Presently it is reported that long-term relaxing, anti-depressive and anxiolytic effects are often observed when IV applications or short term infusions of Procaine are given [51,52]. It has been demonstrated that when procaine is administrated intravenously in humans, it increases blood flow of anterior para-limbic zones and the amygdala cerebral [53] as well as to improve hemodynamic effects of the heart [54]. Other areas of limbic system have been studied when procaine is administered in animal models, finding action on many muscarinic cholinergic receptors of hippocampus. Several authors have been reported procaine actions on many biochemical systems such as dopamine, norepinephrine, serotonin, glutamate, among others. For these reasons, procaine is considered as useful for studying limbic system and emotions [55,56].

In a recent research, it has been pointed out that procaine injection into the ventral tegmental area is able to suppress temporarily the fear conditioned avoidance response in rats and also acts on hippocampal theta rhythms which are related with arousal and attention [57]. Apparently, the metabolites of Procaine are responsible for the additional pharmacologic actions. DEAE is able to act as an anti-inflammatory due to the inhibition of the fatty acid amide hydrolase which causes an increase in endocannabinoid levels [58,59]. The second metabolite PABA operates as an antihistamine, capillary sealant and as a stabilizer for the membranes due to the ester binding with ceramide [60-62].

The increase of infusion effect by combination with sodium-bicarbonate
With the aim of combining the well-known pure alkaline infusion [63] and the pluripotent features of Procaine, the first study was published as the so-called "neural infusion therapy" in 1997 [64]. After impressive positive results were demonstrated in chronic pain patients [65], the method gained popularity very fast in the German-speaking countries and was incorporated into textbooks of pain and neural therapy [66,67]. GLUSA et al. were also able to confirm the vasodilatation effect of the Procaine-Basemixture by using an animal model [68]. An increase of intra-cellular Procaine concentration due to the addition of sodium bicarbonate [69] and

an accelerated initial effect were also observed in animal studies [70,71]. The continuous application of Procaine-Base by the use of a medical pump demonstrated impressive results in many severe cases of pain and inflammation [72-74].

With the osteoarthritic model of rats the anti-rheumatic and joint-protective action of Procaine-Base after intra-articular injection was clearly superior compared to giving the drug Dexamethason [75].

The primary aim of additionally adding the natural buffer-base sodium bicarbonate was its plasmatic degradation influence on Procaine due to the action of serum esterase. All local anesthetics have the common characteristic of general build-up and ionization. These characteristics are essential for their action on the voltage-dependent sodium channels. The unloaded Procaine molecule represents the transporting structure which is able to permeate. The loaded form, Procaine-H+ (ionized form) binds the sodium channel receptor and thus blocks the propagation of an impulse. By changing the pH value of the solution and the terrain, the ionized and non-ionized forms of Procaine can be influenced [76]. It is known that different sodium bicarbonate concentrations can influence the intracellular pH [77].

Initially it was postulated that under more alkaline conditions the conversion of Procaine to para-amino-benzoic acid (PABA) and diethyl-amino-ethanol (DEAE) will be distinctly reduced. Contrary to this assumption it is believed that after intravenously injecting Procaine-Base it gets diluted in the blood of big vessels leading to a quick drop in pH reaching normal physiological levels. In addition, the pulmonary circulation will cause a respiratory compensation of alkalosis. The actual retardation of Procaine degradation can be explained as follows: The pH-dependent dissociation shift explained above will result in increased amounts of well-penetrating transport forms. This is generally typical for all local anesthetics and thus 3-40% of the liberated base is present depending on the pKa value of the anesthetic drug. Besides the distribution in a steady state, the speed of distribution is also important. The speed of distribution is the limiting factor meaning that the diffusion through the membrane is the speed determining step [78]. Accordingly, the distribution depends directly on the lipophilicity of the agent. By shifting the pH, the lipophilic features are changed. A higher amount of free base implies also a higher amount for permeation, which is immediately available to the surrounding tissue and cannot be metabolized so easily by the serum esterase [40].

Practical application of Procaine-Base-Infusions
If there is no prior information concerning the tolerance of Procaine before the infusion, we recommend to make a test application of one drop Procaine 1% into the conjunctiva. Normally, immediately redness (due to increased blood flow) can be observed, a numbness sensation and perhaps a quick burning sensation (due to HCl) can be reported by the patient. If the burning pain persists for some minutes please abstain from parenteral infusions. It is important to highlight that only Procaine-HCl with a pharmaceutical permission

for IV application and without any preservatives (e.g. parabens) should be used.

We recommend to start with a dosage of 50-100 mg Procaine-HCl and 20 ml sodium hydrogen carbonate (8.4%) diluted in a 250 to 500 ml carrier solution. Meanwhile the isotonic sodium chloride solution, used routinely for many years can be exchanged by a similar electrolyte solution to prevent hypernatremia. The infusion takes place for approximately 45 – 60 minutes. By adding increments of 50 mg Procaine-HCl and 10 ml sodium bicarbonate (8.4%), the Procaine-Base infusion will be titrated until the desired therapeutic effect has been reached. For a normal-weight person the maximal dosage of Procaine-HCl is 300 mg (see dosage Table 1). In patients with cardiovascular risk factors we recommend the use of a surveillance technique (EKG, oximetry) for dosages above 300 mg Procaine-HCl. It is advised to ensure an after-treatment observation period of 30 minutes. Furthermore, it is advised to avoid driving for about one hour after treatment. Because of the stability of the Procaine-Base-mixture it should be used up within two hours [because of progressing degradation of Procaine]. Without any prior acid-base diagnostic the Procaine-Base infusion should not be administered more than three times per week with a minimum of one day break between treatment days. A series of 6 to 10 infusions depending on the medical condition have been approved.

Procaine dosage 1 %	sodiumhydrogencarbonate dosage 8.4 %	Sodium chloride 0.9 %	Total volume
100 mg = 10 ml	20 ml	500 ml	530 ml
200 mg = 20 ml	40 ml	500 ml	560 ml
300 mg = 30 ml	60 ml	500 ml	590 ml
400 mg = 40 ml	80 ml	500 ml	620 ml
500 mg = 50 ml	100 ml	500 ml	650 ml

Table 1a: Table of dosage in case of using Procaine 1%.

Procaine dosage 2 %	sodiumhydrogencarbonate dosage 8.4 %	Sodium chloride 0.9 %	Total volume
100 mg = 5 ml	20 ml	500 ml	525 ml
200 mg = 10 ml	40 ml	500 ml	550 ml
300 mg = 15 ml	60 ml	500 ml	575 ml
400 mg = 20 ml	80 ml	500 ml	600 ml
500 mg = 25 ml	100 ml	500 ml	625 ml

Table 1b: Table of dosage in case of using Procaine 2%.

The classic blood parameters for inflammation like blood sedimentation rate and Creactive protein (CRP) should improve after a series of Procaine-Base infusions. Almost always after four till six applications the patients report much better mood and improved overall condition. If there is a positive reaction to the treatment (so-called "responders", in approx. 80 % of patients) it is advised especially in chronic diseases, to continue with a long-term therapy using the helpful dosage for longer intervals, e.g. one till twice a month [34-36].

How safe is the Procaine-Base-Infusion and which side effects appear?

The hypersensitivity to Procaine (also called "para-group allergy") reported in old textbooks with an increased allergy rate has not been confirmed yet [79,80].

After over 450.000 applications of neural therapy infusions according to the described regime in our clinic and outpatient department, we have not observed one case with long-term or severe side effects. No case was registered with a serious allergic emergency situation, which underlines the observations of BECKE concerning the huge therapeutic safety of Procaine [58]. Sometimes patients report of heart palpitation (6%) and profuse sweating (5%). According to our experience patients which are using nitro compounds, calcium antagonists and beta-blockers seem to have a higher disposition to these side effects. Apparently in such cases the reflective and oversegmental disinhibiting effect of the anesthesia dominates over the negative-ionotropic and negative-rhythmotropic potential of Procaine. As expected, in approximately 6% of patients a short-time reduction in blood-pressure and vasovagal syncope situations can occur during the application. All these symptoms disappear within few minutes, especially after reducing the infusion speed [34,63].

Some patients report about sleep disorders (5%) and a general hyperactive feeling till one day after finishing the infusion, which does not reduce the physical working capacity. Approximately 4,5% of treated persons complained of temporary headaches and slight vertigo. Especially during the first couple of infusions such reactions can occur in scope of a so-called "first reaction" (HERING´s effect) according to the holistic thinking in neural therapy [1] and homeopathy [81].

Indications and contraindications of Procaine-Base-Infusions

The multiple therapeutic effects of Procaine in combination with an alkaline additive are responsible for the enormous palette of medical indications (tab. 3a). Especially all kind of pain, inflammatory and auto-immune diseases, vegetative imbalances in addition to the complementary cancer treatments are of primary importance.

Acute situations	Radicular syndrome, pseudo-radicular syndrome, acute infection, early stage of algodystrophy, sudden deafness, inflammations, Migraine, activated osteoarthrosis, postoperative pain treatment
Chronic pain	Multiple arthralgia, chronic radicular-/pseudo-radicular syndrome, Algodystrophy, all kinds of neuralgia, facet pain syndrome
Chronic inflammations	Lupus erythematosus, rheumatoid arthritis, psoriatic arthritis, scleroderma, neurodermatitis, multiple sclerosis, crohn´s disease, ulcerative colitis, polymyalgia rheumatica
Others	Periphery circulatory disorders, constipation, dysmenorrhea clinical and para-clinical hints for tissue acidosis, osteoporosis complementary cancer therapy, pre- and post-operative

Table 3a: Main indications of Procaine-Base-Therapy.

The few contra-indications should receive attention in practice

which are summarized in table 3b.

Patient	Hypersensitivity towards Procaine, Neurosis or Psychosis with unclear compliance See also expert information at Procaine and Na-bicarbonate producers
Therapist and Staff	Lack of knowledge in handling local anesthetics, inadequate educated staff, Under-resourced rooms and lack of adequate emergency equipment

**Table 3b:** Contra-indications of Procaine-Base therapy.

Current status: Procaine-Base-Infusion adapted to the acid-base-balance

It is important to emphasize that according to the above described procedure of Procaine-Base-infusion, a daily application of such a high dose of sodium bicarbonate is inacceptable. SAHA reported that after a total of seven Procaine-Base-infusions with daily increasing dosages up to a maximum of 300 mg Procaine-HCl and 120 ml 8,4% sodium bicarbonate, 3 out of 13 patients showed clinical symptoms of metabolic alkalosis [82]. Before and after these series of infusions the base excess (BE) measured via arterial blood gas analysis was determined and in all cases amounted to over plus two, which indicates a verified metabolic alkalosis. This kind of daily treatment only applies for patients with an adequate acid-base homeostasis. The body intrinsic buffer system should not be overloaded.

However, patients having a metabolic alkalosis with a reduced compensatory ability in acid-base balance are increasing. Quite often this is found in cases of verproteinization, advanced stages of cancer, liver weakness and putrefaction dysbiosis of the large intestine. Furthermore, the use of antacids, alkaline powders, loop diuretics and too much sodium intake enhances the shift in the acid-base-balance towards alkalosis [83,84]. For the practical analysis of the acid-base balance we prefer the venous blood titration system BUFFY® over the arterial blood gas analysis (aBGA, see [85-88]) because it is hematocrit-adapted and calibrated to 37°Celsius. The test gives very good information about the buffer capacity of whole blood and plasma and indicates exactly the amount of base needed [88,89]. Metabolic alkalosis can also occur in hyponatremia, hypokalemia and in increased ammonia levels (in EDTA plasma). In cases of inflammatory, cardiac and renal dysfunctions, rheumatic and pain-related diseases a metabolic acidosis is mostly likely detected [91]. These patients have an increased need of a buffer base and should receive sodium bicarbonate ranging from 60-120 ml (8,4% solution) in addition to Procaine.

In contrast to cases of metabolic alkalosis there is only a small or no need of additional base treatment. In this case, we only administer infusions of Procaine-HCl together with a carrier solution. In addition we suggest to give 3-5 ampules of L(+)-lactic acid.

In figure 2 the pH-values of different concentrations of Procaine-HCl, different alkaline mixtures and basic solution volume as well as the pure Procaine-HCl solution are compared.

Figure 3: pH-value of Procaine-Base-Infusion (PBI) in three different concentrations, base mixture (1,68%) and pure Procaine-Hcl.

Examples from treated patients

The following case reports shall underline the various possibilities to use the method in different kinds of diagnosis:

Case 1

juvenile rheumatoid arthritis: patient H.R., 34 years old, started with 3 years, ellbow, ankle, MCP hands, knees, Iritis

State before (9th August 2016): knee swelling right, joint pain in knees, shoulders and ankles, many years MTX and Remicade®, Prednison and NSAR in intervals, would like to come away from pharmaceutical drugs, will change her lifestyle completely, RF positive, CRP 61 mg/l, aBGA: pH: 7.42, BE: - 2.1 mmol/l, Vitamin A and D low, anemia

Therapeutic procedure: first series (10x) Procaine-Base-Infusion (PBI) weekly (titration till 300 mg Procaine and 100 ml 8,4% Na-bicarbonate), due to much better general condition continuation of infusion twice per month

Additional complementary treatment: change of diet (vegetarian), supplementation with Bosvay® 3x500 mg, Antioxidant complex, Epogam omega 6, Omni Biotic stress repair®, Vitamin D3 3000 IU, Vitamin A, Chlorella 3x3 tabl., Solidago comp. 3x3 drops

Follow up: very fast reduction of pain, stiffness and joint swelling, very good general condition, has stopped conventional medication after 8 weeks, QBC normal

Last Consultation 21.9.2017: "I am very happy, all my problems are approximately 95% better, no more swelling of the knee, I am delighted, and since three weeks I am sure: I am pregnant!".

Case 2

deep Foot Ulceration and chronic Osteomyelitis: patient H.S, 56 years old, state after kidney transplantation, cytostatic therapy (see figure 4a-c)

State before Procaine treatment (17th April 2009): all together 12 (!) operations during four months stay at the university hospital, multiple rejection reactions after autologous skin transplantations, wound healing disorders on harvesting points, CRP 98,5 mg/l, highly inflammatory ulceration of the dorsum of foot, partly extensor tendons and bones are visible, buffy test with metabolic

acidosis,

Therapeutic procedure: 2x per week Procaine-Base-infusion (titration till 500 mg Procaine and 120 ml 8,4% sodium bi-carbonate),

Follow up: 25.5.09: CRP: 23.3 mg/l, wounds on forearm and upper leg completely healed, ulceration foot 80% closed, pain reduced from VAS 8 to 2-3, Opioid drug (Tilidin ret. 200 mg) discontinued, 17.6.09: CRP: 6.8 mg/l, foot wound also complete dry, increase of motion training, 4.10.09: maintenance dose 1 tablet ProcClusterR 50 mg, very beneficial, no recurrence till today,

Additional complementary treatment: exposure to ozone gas locally (two month), homeopathic remedies, anti-oxidative acting supplement complex, alkaline-rich and hypo-allergic food.

Comment: Together with the anti-inflammatory and vasodilating features of procaine the known problem of metabolic alkalosis in patients with chronic kidney diseases and after transplantation can be solved by the combination with sodium bi-carbonate [92,93].

Figure 3: Follow up of the case two.

Case 3

psoriatic Arthritis: patient R.N, 60 years old, suffering from psoriatic arthritis since ten years, additional symptoms are chronic fatigue, depression, hypertension, sleep apnea

State before Procaine treatment (11th November 2016): diffuse muscle cramps and pain permanently between VAS 6-7 despite complex medication (Sirdalud®, Relaxane®, Ibuprofen, Prednisolon 12,5 mg, Novaminsulfon (2x500 mg), Otezla® 60 mg), awkward gait with two crutches, intensive pain and reduction of movement left shoulder, hip and metacarpophalangeal joints both sides, CRP 41 mg/l, aBGA: pH: 7.43, BE: 2.1 mmol/l

Therapeutic procedure: first series (10x) PBI twice a week (titration till 400 mg Procaine), due to much better general condition continuation of infusion weekly

Follow up: Stepwise reduction of pain till VAS 1-2, successful reduction of pain medication to the half amount including Otezla®, much better general condition, mood distinct brightened, energy feeling significantly better, swelling and restriction of movement in affected joints marked improved, control CRP < 5 mg/l, after 20 Procaine infusions the patient is almost painless, happy, has stopped using NSAR and Otezla®

Additional complementary treatment: start with alkaline-rich nutrition, supplementation with Vitamin E (800 IE) and antioxidant complex, frankincense (Bosvay®,3x800 mg), Harpagophytum (3x480 mg)

Comment: The positive effect of neural therapy and intravenously

injected procaine is mentioned in old literature [94].

Case 4

Sclerodermia: patient H.S., 48 years old, disease started in 2010, State before Procaine treatment (19th March 2011): joint pain, coldness of fingers, dysaesthesia, dry eyes

Therapeutic procedure: six weeks PBI with increasing dosage, after two months changeover to PBI monthly

Follow up: has a good effect meanwhile over a period of six years Additional complementary treatment: change of diet, removal of amalgam and appropriate detox, probiotics for intestinal health.

Conclusion and Outlook

After the empirical start twenty years ago the Procaine-Base-infusion treatment meanwhile reached a well-accepted level of clinical importance and has advanced as routine therapy in many hospitals and outpatient departments for pain treatment, rehabilitation and natural medicine. Even if scientific findings convincingly confirm the Procaine-Base mechanism of action, spectrum of indications and the individualized application, more research and scientific studies are warranted.

It is very important for the authors of this article to emphasize that the treatment method of Procaine is conducted properly, especially to individualize the therapy according to the acid-base-homeostasis and clinical parameters of the patient [95]. Finally, it is noticeable that the method is not a replacement for neural therapy injections, especially for treatment of neuro-modulative triggers.

References

1. Hahn-Godeffroy JD. Procaine in the neural therapy after Huneke. German. Der Allgemeinarzt. 1993; 14: 34-38.
2. Donaldson LF. Local anaestesia prevent acute inflammatory changes in neuropeptide messenger RNA expression in rat dorsal root ganglia neurons. Neuroscience Letters. 1994; 175: 111-113.
3. Levine R. The contribution of neurogenic inflammation in experimental arthritis. J Immunol. 1985; 135: 343-347.
4. Krause W. ID-Pharma, Research materials. German. 2000.
5. Fischer L, Ludin SM, Puente DE LA Vega K, et al. Neuralgia of the glossopharyngeal nerve in a patient with posttonsillectomy scarring: recovery after local infiltration of procaine-case report and pathophysiologic discussion. Case Rep Neurol Med. 2015; 560546.
6. Kasch H. The scavanger effect of a definded procaine base mixture. Presentation german pain congress. German. 2000.
7. Rusu C, Borsa C. Antioxidant and lipid-lowering effects of the original Procaine-based products. Rom.J Geront Geriatr. 1996; 3: 47-61.
8. Dolganiuc A, Radu D. Procaine and diethylaminoethanol influence on the release of free oxygen radicales by polymorphonuclear leukocytes, in rabbits and humans. Rom Arch Microbiol Immunol T. 1998; 57: 23-32.
9. Huang Y. Studies on vasorelaxation by tetrapentylammonium ions in rat aortic rings. Life Sci. 1997; 61:1811-1817.
10. Willatts DG, Reynolds F. Comparison of the vasoactivity of

amide and ester local anaesthetics. An intradermal study. Br J Anaesth. 1985; 10: 1006-1011.

11. Wills MH, Johns RA, Stone DJ, et al. Vascular effects of 2-chloroprocaine and sodium metabisulfite on isolated rat aortic rings. Reg Anesth. 1989; 14: 271-273.

12. Fulton D, Mcgiff JC, Quilley J. Role of K+ channels in the vasodilator response to bradykinin in the rat heart. Br J Pharmacol. 1994; 113: 954-958.

13. Adeagbo AS, Malik KU. Endothelium-dependent and BRL 34915-induced vasodilatation in rat isolated perfused mesenteric arteries: role of G-proteins, K+ and calcium channels. Br J Pharmacol. 1990; 100: 427-434.

14. Willatts DG, Reynolds F. Comparison of the vasoactivity of amide and ester local anaesthetics. An intradermal study. Br J Anaesth. 1985; 57: 1006-1011.

15. Mutschler H. Drugs effects. Springer Publ. 8th German edn. 2001; 267.

16. Becke M. The effect of Procain on the cell membrane. German Arztezeitschrift f Naturheilverfahren. 1996; 37: 2: 90-97.

17. Wander R. Actions of Procaine in the ground substance. German. Personal information. 1999.

18. Hille B. Ionic channels of excitable membranes, 2nd ed, Sunderland. 1992.

19. Jurius AR, Jarrush-Saadeh D, Nassar C. Modulation of some human mononuclear cells activities by procaine. Middle East J Anaesthesiol. 1988; 9: 417-428.

20. MROSE HE, RITCHI JM: Local anestetics: Do Benzocaine and Procaine act on the same singlesite?, J. Gen.Physiol. 70: 223-225 (1978).

21. Jalili S, Saeedi M. Study of procaine and tetracaine in the lipid bilayer using molecular dynamics simulation. Eur Biophys J. 2017; 46: 265-282.

22. Yau TM, Kim SC. Local anaesthetics as hypoxic radiosensitizers, oxic radioprotectors and potentiators of hyperthermic killing in mammalian cells. Br J Radiol. 1980; 53: 687-692.

23. Feinendegen LE, Muhlensiepen H, Lindberg C, et al. Acute and temporary inhibition of thymidine kinase in mouse bone marrow cells after low-dose exposure. Int J Radiat Biol Relat Stud Phys Chem Med. 1984; 45: 205-215.

24. Chlebowski RT, Block JB, Cundiff D, et al. Doxorubicin cytotoxicity enhanced by local anesthetics in a human melanoma cell line. Cancer Treat Rep. 1982; 66: 121-125.

25. Esposito M, Viale M, Vannozzi MO, et al. Effect of the antiarrhythmic drug procainamide on the toxicity and antitumor activity of cis-diamminedichloroplatinum(II). Toxicol Appl Pharmacol. 1996; 140: 370-377.

26. Viale M, Pastrone I, Pellecchia C, et al. Combination of cisplatin-procaine complex DPR with anticancer drugs increases cytotoxicity against ovarian cancer cell lines. Anticancer Drugs. 1998; 9: 457-463.

27. Pastrone I, Viale M, Cafaggi S, et al. Effect of the cisplatin-Procaine complex DPR in combination with several anticancer agents on murine P388 leukemic cells in vitro and in vivo. Invest New Drugs. 1999; 16: 297-302.

28. Villar-Garea A, Fraga MF, Espada J, et al. Procaine is a DNA-demethylating Agent with Growth-inhibitory Effects in Human Cancer Cells. Cancer Research. 2003; 63: 4984-4989.

29. Villar-Garea A: Epigenetic transcriptional repression of tumour suppressor genes and its reversion by drugs. Doctoral thesis. Chemical Sciences. Department of Biochemist and Molecular Biology of Univesity of Valencia. Mayo. 2005.

30. Imazeki F, Fukai K, et al. Procaine inhibits the proliferation and DNA methylation in human hepatoma cells. Hepatol Int. 2007; 1: 355-364.

31. Sabit H, Samy MB, Said O, et al. Procaine Induces Epigenetic Changes in HCT116 Colon Cancer Cells. Genetics Research International. 2016.

32. Adinoff B, Devous MD, Best S, et al. SPECT following intravenous procaine in cocaine addiction. Ann N Y Acad Sci. 1999; 877: 807-810.

33. Adinoff B, Devous MD SR, Best SM, et al. Limbic responsiveness to procaine in cocaine-addicted subjects. Am J Psychiatry. 2001; 158.

34. Adinoff B, Devous MD SR, Cooper DC, et al. Neural response to lidocaine in healthy subjects. Psychiatry Res. 2009; 173: 135-142.

35. Adinoff B, Devous MD, Best Se, et al. Dose-response measures of rCBF and subjective changes following procaine in healthy female volunteers. Psychiatry Res. 2002; 114: 123-135.

36. Wilcox KM, Kimmel HL, Lindsey KP, et al. In vivo comparison of the reinforcing and dopamine transporter effects of local anesthetics in rhesus monkeys. Synapse. 2005; 58: 220-228.

37. Seifen AB, Ferrari AA, Seifen EE, et al. Pharmacokinetics of intravenous procaine infusion in humans. Anesth Analg. 1979; 58: 382-386.

38. Smith RH, Hunt DH, Seifen AB, et al. Pharmacokinetic model for procaine in humans during and following intravenous infusion. J Pharm Sci. 1979; 68: 1016-1022.

39. Layer P, Bronisch HJ, Henniges UM, et al. Effects of systemic administration of a local anesthetic on pain in acute pancreatitis: a randomized clinical trial. Pancreas 2011; 40: 673-679.

40. Meng W, Yuan J, Zhang C, et al. Parenteral analgesics for pain relief in acute pancreatitis: a systematic review. Pancreatology. 2013; 13: 201-206.

41. Lankisch PG. Procain Infusion in Pain Treatment of Acute Pancreatitis: yes or no, that is the Question. Z Gastroenterol 2012; 50: 323-324.

42. Veneziano G, Tobias JD. Chloroprocaine for epidural anesthesia in infants and children. Paediatr Anaesth. 2017; 27: 581-590.

43. Lee SC, Moll V. Continuous Epidural Analgesia Using an Ester-Linked Local Anesthetic Agent, 2- Chloroprocaine, During Labor: A Case Report. A Case Rep. 2017.

44. Veneziano G, Iliev P, Tripi J, et al. Continuous chloroprocaine infusion for thoracic and caudal epidurals as a postoperative analgesia modality in neonates, infants, and children. Paediatr Anaesth. 2016; 26: 84-91.

45. Muhly WT, Gurnaney HG, Kraemer FW, et al. A retrospective comparison of ropivacaine and 2-chloroprocaine

continuous thoracic epidural analgesia for management of postthoracotomy pain in infants. Paediatr Anaesth. 2015; 25: 1162-1167.

46. Kamata M, Corridore M, Tobias JD. Thoracic epidural infusion with chloroprocaine for postoperative analgesia following epicardial pacemaker placement in an infant. J Pain Res. 2014; 23: 609-613.

47. Landriscina DM: The effect of pH-adjusted 2-chloroprocaine on the duration and quality of pain relief with a subsequent continuous epidural bupivacaine infusion. AANA J. 1992; 60: 174-180.

48. Tobias JD, Rasmussen GE, Holcomb GW, et al. Continuous caudal anaesthesia with chloroprocaine as an adjunct to general anaesthesia in neonates. Can J Anaesth. 1996; 43: 69-72.

49. Tobias JD, O'Dell N. Chloroprocaine for epidural anesthesia in infants and children. AANA J. 1995; 63: 131-135.

50. O'donnell CP, Scheuer DA, Keil LC, et al. Cardiac nerve blockade by infusion of procaine into the pericardial space of conscious dogs. Am J Physiol. 1991; 260: R1176-1182.

51. Hahn-Godeffroy JD: Procaine-Reset. A therapeutical concept to treat chronic diseases. German. Schweiz Z Ganzheitsmed. 2011; 23: 291-296.

52. Herdegen T, Mangold S, Hahn-Godeffroy JD. Therapeutic effects of Procaine Infusions: Result of a multicentric observation study. German. Presentation medical week Baden-Baden 2016.

53. Ketter TA, Andreason PJ, George MS, et al. Anterior paralimbic mediation of procaine-induced emotional and psychosensory experiences. Arch Gen Psychiatry. 1996; 53: 59-69.

54. Waaben J, Sorensen O, Wiberg-Jorgensen F, et al. Haemodynamic effects of intravenous procaine as a supplement to general anaesthesia in patients with valvular heart disease. Acta Anaesthesiol Scand. 1984; 28: 34-36.

55. Benson B, Carson R, Kiesewetter D, et al. Potential Cholinergic Mechanism of Procaine's Limbic Activation. Neuropsychopharmacology. 2004; 9: 1239-1250.

56. Butterworth JFT, Cole LR. Low concentrations of procaine and diethylaminoethanol reduce the excitability but not the action potential amplitude of hippocampal pyramidal cells. Anesth Analg. 1990; 71: 404-410.

57. Matulewicz P, Orzeł-Gryglewska J, Braszka L, et al. Hippocampal theta rhythm after local administration of procaine or amphetamine into the ventral tegmental area in fear conditioned rats. Neurosci Lett. 2015; 589: 132-137.

58. Little JW, Ford A, Symons-Liguori AM, et al. Endogenous adenosine A3 receptor activation selectively alleviates persistent pain states. Brain. 2015; 138: 28-35.

59. Vandevoorde S, Lambert DM, Smart D, et al. N-Morpholino- and N-diethyl-analogues of palmitoylethanolamide increase the sensitivity of transfected human vanilloid receptors to activation by anandamide without affecting fatty acid amidohydrolase activity. Bioorg Med Chem. 2003; 11: 817-825.

60. Abounassif MA, El-Obeid HA, Gadkariem EA: Stability studies on some benzocycloheptane antihistaminic agents. J Pharm Biomed Anal. 2005; 36: 1011-1018.

61. Uchiyama M, Oguri M, Mojumdar EH, et al. Free fatty acids chain length distribution affects the permeability of skin lipid model membranes. Biochim Biophys Acta. 2016; 858: 2050-2059.

62. Paloncyova M, Devane RH, Murch BP, et al. Rationalization of reduced penetration of drugs through ceramide gel phase membrane. Langmuir. 2014; 30: 13942-13948.

63. Worlitschek K: Practice of acid base household. German. Haug Publisher, 6th Edn, 2012; 117.

64. Reuter U, Oettmeier R: Regulation and pain treatment with infusion neural therapy. German. Natura Med. 1997; 12: 20-25.

65. Reuter U, Oettmeier R. The high-dosed Procaine-Base-Infusion. German. Arztezeitschrift f. Naturheilverfahren. 1999; 11: 776-783.

66. Berg Fvd. (Eds). Applied Physiology, Volume 4. Understanding and influencing pain. German. Thieme Publisher Stuttgart. 2004.

67. Weinschenk S (Eds). Handbook of Neural Therapy - Diagnostics and Treatment with local Anesthetics. German. Urban and Fischer. 2010.

68. Glusa E. Spasmolytic action of Procaine-Base on the aorta of rats. German. ID-Pharma, Research material. 1999.

69. Ibusuki S, Kasuki H, Takasaki M. The effects of extracellular pH with and without bicarbonate on intracellular Procaine concentrations of anesthetic effects in crayfish giant cells. Anesthesiology. 1998; 88: 1549-1557.

70. Yung E, Lahoti T, Jafari S, et al. Bicarbonate plus epinephrine shortens the onset and prolongs the duration of sciatic block using chloro-Procaine followed by bupivacaine in sprague-dawley rats. Reg Anesth Pain Med. 2009; 34: 196-200.

71. Stevens RA, Chester WL, Grueter JA, et al. The effect of pH adjustment of 0.5% bupivacaine on the latency of epidural anesthesia. Reg Anesth. 1989; 14: 236-239.

72. Oettmeier R, Reuter U. The continuous Procaine-Basen infusion/-perfusion: New ways for systemic influencing regulation, inflammation and pain. German. Erfahrungsheilkunde. 2000; 2: 75-84.

73. Iudenkov NF. Intra-arterial infusion of penicillin and procaine in treatment of suppurative inflammations and open trauma. Russian. Voen Med Zh. 1959; 86: 77-79.

74. Fuzaylov G, Kelly TL, Bline C, et al. Post-operative pain control for burn reconstructive surgery in a resource-restricted country with subcutaneous infusion of local anesthetics through a soaker catheter to the surgical site: Preliminary results. Burns. 2015; 41: 1811-1815.

75. Brauer. The anti-rheumatic and joint-protective effect of a defined Procaine-Base mixture. German. Presentation german pain congress. German. 2000.

76. Kasch H, Engert B, Reuter U, et al. Internal research materials. German. Jen Cluster GmbH Jena, 2009.

77. Levraut J, Labib Y, Chave S, et al. Effect of sodium bicarbonate on intracellular pH under different buffering conditions. Kidney Int. 1996; 49: 1262-1267.

78. Langguth P, Fricker G, Wunderli-Allenspach H. Biopharmacy, German. Weinheim, Wiley-VCH-Publisher. 2004.

79. Becke M. Procaine and the discussion concerning the allergy. German. Arztezeitschrift f Naturheilverfahren. 1996; 37: 12: 908-912.

80. Hahn-Godeffroy JD. Concerning the indispensability of Procaine in neural therapy. German. Arztezeitschrift f Naturheilverfahren. 1993; 3: 722-730.

81. Cleave E. Cleave's biographical cyclopaedia of Pennsylvania. 1874.

82. Saha FJ. Procaine-Infusions in neural therapy - with or without alkalic additive? Presentation medical week Baden-Baden. 2016.

83. Oettmeier R, Reuter U. Examinations concerning the importance of metabolic alkalosis in cancer patients. German. Umwelt Medizin Gesellschaft. 2017; 30: 15-18.

84. Luke RG, Galla JH. Does chloride play an independent role in the pathogenesis of metabolic alkalosis? Semin Nephrol. 1989; 9: 203-205.

85. Lynch F. Arterial blood gas analysis: amplications for nursing. Paediatr Nurs. 2009; 21: 41-44.

86. Mandy J. Arterial blood gas analysis. 1: Understanding ABG reports. Nurs Times. 2008; 104: 28-29.

87. Allen K. Four-step method of interpreting arterial blood gas analysis. Nurs Times. 2005; 101: 42-45.

88. Woodrow P. Arterial blood gas analysis. Nurs Stand. 2004; 18: 45-52.

89. Van Limburg Stirum J. Modern Acid-Base-Medicine. German. Hippokrates. 2008.

90. Van Limburg Stirum J. The Acid-Base Household - Diagnostics and Concepts for Treatment. German. DHZ. 2006; 3: 29-33.

91. Shapiro JI. Pathogenesis of cardiac dysfunction during metabolic acidosis: therapeutic implications. Kidney Int Suppl. 1997; 61: 47-51.

92. Ortega LM, Arora S. Metabolic acidosis and progression of chronic kidney disease: incidence, pathogenesis, and therapeutic options. Nefrologia. 2012; 32: 724-730.

93. Batlle DC, Mozes MF, Manaligod J, et al. The pathogenesis of hyperchloremic metabolic acidosis associated with kidney transplantation. Am J Med. 1981; 70: 786-796.

94. Tello EE. Treatment of psoriasis with novocaine injected intravenously; preliminary report. Spanish. Prensa Med Argent. 1953; 40: 3161-3163.

95. Oettmeier R, Reuter U, Engert B, et al. The Procaine-Base-Infusion: 20 years of experience of an alternative use with several therapeutic effects. J of CAM (submitted for publication).